PROTOKOLwiki
COMPOUNDS / ADAPTOGEN / GINKGO BILOBA
ADAPTOGEN

GINKGO BILOBA

LOW RISK
BEST FOR:Cognition●●●●●○○○○○5/10
GINKGO BILOBA · EGB 761 · GINKGO BILOBA EXTRACT · GBE · MAIDENHAIR TREE · FOSSIL TREE · GINKGO · TANAKAN · RÖKAN · TEBONIN · GINKGOLIDES
NootropicAntioxidantNeuroprotectiveHerbal ExtractCognitive Support

Plant extract with antioxidant and neuroprotective properties used for cognitive impairment and dementia.

ROUTE / DOSAGE
LOW40mg
STANDARD120-240mg
HIGH600mg+
Note: Standardized EGb 761 extract; 240mg/day is the evidence-based dose for cognitive impairment
CYCLE
Daily use 8-12 week cycles common
BIOAVAILABILITY
30-60% oral
ACTIVE DURATION
4-8h (subjective)
STORAGE
Room temperature dry away from light
HALF-LIFE
2-4h (plasma)
DURATION BREAKDOWN
Total4-8h
Onset30min-2h
Come up1-2h
Peak2-4h
Offset2-4h
After effects4-8h
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
6 documented
Improved cerebral blood flow
Antioxidant and free radical scavenging
Anti-inflammatory effects
Reduced platelet aggregation
Potential cognitive stabilization in dementia
Neuroprotective against excitotoxicity
§ 02 — RISKS
Increased bleeding risk when combined with anticoagulants or antiplatelet drugs
Potential drug interactions via microsomal enzyme inhibition affecting bioavailability of co-administered medications
Possible interactions with MAOIs, alprazolam, haloperidol, and nifedipine
May promote ovarian granulosa cell apoptosis and suppress ovarian folliculogenesis
Gastrointestinal disturbances reported at higher doses
§ 03 — INTERACTIONS
No interaction with your stack
VIEW STACK
CAUTION
MAOIs
Alprazolam
Haloperidol
Nifedipine
AVOID · DANGEROUS
Warfarin
Antiplatelet agents
§ 04 — SCIENCE

Multiple randomized controlled trials and meta-analyses have investigated EGb 761 for cognitive impairment and dementia, with dosages of 240 mg/day showing statistically significant benefits in cognition, activities of daily living, and global assessment compared to placebo over 22-26 week periods. A 2025 meta-analysis of 782 patients with mild dementia confirmed significant superiority over placebo in cognition, daily functioning, and quality of life with medium to large effect sizes. However, efficacy in preventing dementia remains controversial, and added benefits over conventional anti-dementia treatments are scarcely investigated. Safety data generally show no important safety concerns, with adverse event frequencies similar to placebo. Evidence for tinnitus and acute mountain sickness indications has not shown beneficial effects.

§ 06 — SOURCES
[1]
Ginkgo biloba: indications, mechanisms, and safety
pubmed.ncbi.nlm.nih.gov ↗
[2]
Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders
pubmed.ncbi.nlm.nih.gov ↗
[3]
Ginkgo biloba - Am Fam Physician
pubmed.ncbi.nlm.nih.gov ↗
[4]
Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis
pubmed.ncbi.nlm.nih.gov ↗
[5]
Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia - a meta-analysis
pubmed.ncbi.nlm.nih.gov ↗
[6]
Ginkgo biloba and Its Chemical Components in the Management of Alzheimer's Disease
pubmed.ncbi.nlm.nih.gov ↗
[7]
Ginkgo biloba--an appraisal
pubmed.ncbi.nlm.nih.gov ↗
[8]
Potential effects of ginkgo (Ginkgo biloba, L.) on female reproduction
pubmed.ncbi.nlm.nih.gov ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT